BioSyntech announces management changes

LAVAL, QC, Dec. 2 /CNW/ - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that Ms. Antoinette Lizzi, Chief Financial Officer, will leave the Company effective December 2, 2009 and Ms. Catherine Auld, CA, will join the Company as Chief Financial Officer.

"Ms. Auld has been a consultant to BioSyntech since September and will bring her numerous years of experience working with public biotechnology companies to BioSyntech in her new role as Chief Financial Officer," said Ms. Jeanne M. Bertonis, Chief Executive Officer of BioSyntech. "I would like to thank Ms. Lizzi for her contributions to the Company this year and I wish her the best in future initiatives."

For more than eight years, Ms. Auld has worked with public and private biotechnology companies with responsibilities for public company reporting, initial public offerings, financing, licensing and partnership activities. Previously, she was the Chief Financial Officer for NeuroMedix Inc., Transition Therapeutics Inc. and PreMD Inc.; Interim Chief Financial Officer for ARIUS Research Inc.; and Vice President of Finance for Cervelo Pharmaceuticals Ltd. Prior to working in the biotechnology industry Ms. Auld was a senior manager with KPMG LLP.

About BioSyntech

BioSyntech is a medical device Company specialized in the development, manufacturing and commercialization of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's platform technology is a family of hydrogels called BST-Gel(R), some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel(R) is currently undergoing an international pivotal trial. For additional information, visit

Forward-Looking Statements

This press release contains forward-looking statements and information which are subject to material risks and uncertainties. Such statements are not historical facts and are based on the current expectations of management. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of BioSyntech's products, the availability of government and insurance reimbursements for BioSyntech's products, the strength of our intellectual property, the success of our research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in BioSyntech's annual report and other documents filed from time to time with the Canadian securities commissions which are available at These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumstance or otherwise, except in accordance with law.

%SEDAR: 00020217EF


For further information: For further information: Casey Gurfinkel, The Equicom Group, (416) 815-0700 x283,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890